5 Reasons Novartis Shareholders Aren't Shaken

Novartis has defended its decision to sit on knowledge of false pre-clinical data related to Zolgensma's manufacturing process, and the stock price has already returned to levels seen ahead of the FDA's stern letter of complaint. Here are five reasons the company and its shareholders don't seem the least bit bothered.